Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Hidenori, Urata"'
Publikováno v:
International Journal of Cardiology. Cardiovascular Risk and Prevention, Vol 24, Iss , Pp 200359- (2025)
Purpose: To examine the efficacy and safety of pemafibrate in outpatients with hypertriglyceridemia, including alcoholic hypertriglyceridemia. Method: This multicenter, open-label, prospective observational study (C20-07-009) included outpatients wit
Externí odkaz:
https://doaj.org/article/c7de3cb137284e96a86e9045ea37ce06
Autor:
Motoyasu Miyazaki, Hitomi Hirata, Satoko Takaki, Momoko Misaki, Yukako Mori, Kaoko Tokura, Natsuki Sato, Akio Nakashima, Atsuko Yanagida, Isa Okajima, Hidenori Urata, Osamu Imakyure
Publikováno v:
Pharmacy, Vol 12, Iss 5, p 153 (2024)
Medication adherence is important for the appropriate drug-based treatment in patients with chronic diseases, especially those with cardiovascular diseases (CVDs). The purpose of the present study was to evaluate medication adherence among patients w
Externí odkaz:
https://doaj.org/article/be0e12d6e3bf4f218287db6acaa86fe3
Publikováno v:
Clinical and Experimental Hypertension, Vol 42, Iss 6, Pp 545-552 (2020)
Background Renin is the starting point of the renin angiotensin (RA) system cycle. Aliskiren (AL), which is a direct renin inhibitor, suppressed the entire RA cycle. In the present study, the efficacy of add-on of AL treatment in patients with essent
Externí odkaz:
https://doaj.org/article/dd08cac8df8446c59f67aad6834f8d93
Publikováno v:
Clinical and Experimental Hypertension, Vol 42, Iss 5, Pp 438-448 (2020)
Background: This study investigated whether a combination drug containing an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB) could provide effective antihypertensive therapy. Methods: A multicenter, prospective, open-label s
Externí odkaz:
https://doaj.org/article/0a25126994704a9b9dc743846f96d310
Autor:
Yosuke Takamiya, Keisuke Okamura, Kazuyuki Shirai, Tetsu Okuda, Kunihisa Kobayashi, Hidenori Urata
Publikováno v:
Clinical and Experimental Hypertension, Vol 42, Iss 3, Pp 197-204 (2020)
Objective: We purpose to confirm the effect of teneligliptin (Tenelia), a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, on glycemic control and non-glucose risk factors for macroangiopathy, including blood pressure, lipid metabolism, and body w
Externí odkaz:
https://doaj.org/article/dc5d542dfb4c4a4689dc9a1a46eae9c1
Autor:
Motoyasu Miyazaki, Koichi Matsuo, Masanobu Uchiyama, Yoshihiko Nakamura, Yuya Sakamoto, Momoko Misaki, Kaoko Tokura, Shiro Jimi, Keisuke Okamura, Sen Adachi, Tomohiko Yamamoto, Kazuyuki Shirai, Hidenori Urata, Osamu Imakyure
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 6, Iss 1, Pp 1-11 (2020)
Abstract Background Inappropriate dosing of direct oral anticoagulants (DOACs) has been associated with clinical safety and efficacy; however, little is known about clinical data associated with an inappropriate DOAC dosing in Japan. In addition, the
Externí odkaz:
https://doaj.org/article/ceba16bf961246adabeb4c98dae885b4
Publikováno v:
Clinical and Experimental Hypertension, Vol 41, Iss 8, Pp 717-725 (2019)
Background and Purpose: Human chymase (h-chymase) is a serine protease that forms local angiotensin II and has been proven to be related to onset of hypertension, arteriosclerosis, and post myocardial infarction cardiac remodeling. Since no chymase i
Externí odkaz:
https://doaj.org/article/0537be9a6352404bbe79ba51765f271a
Autor:
Tuba M. Ansary, Maki Urushihara, Yoshihide Fujisawa, Sayaka Nagata, Hidenori Urata, Daisuke Nakano, Hitomi Hirofumi, Kazuo Kitamura, Shoji Kagami, Akira Nishiyama
Publikováno v:
Experimental Physiology, Vol 103, Iss 11, Pp 1524-1531 (2018)
New Findings What is the central question of this study? Can chymase inhibition prevent angiotensin I‐induced hypertension through inhibiting the conversion of angiotensin I to angiotensin II in the kidney? What is the main finding and its importan
Externí odkaz:
https://doaj.org/article/e7beb4db97c246ada223dc20da34ce8a
Publikováno v:
Clinical and Experimental Hypertension, Vol 40, Iss 2, Pp 99-106 (2018)
Objective: When hypertension is uncontrolled by routine treatment with an angiotensin II receptor blocker (ARB) and the calcium channel blocker amlodipine (5 mg), the dose of amlodipine can be increased or a diuretic can be added. We investigated the
Externí odkaz:
https://doaj.org/article/5f48ef1cc4ba46e6bbab18e94458c070
Publikováno v:
Clinical and Experimental Hypertension, Vol 40, Iss 2, Pp 112-117 (2018)
The aim of the present study was to establish a convenient clinically applicable assay method for chymase-dependent angiotensin II forming activity of circulating mononuclear leukocytes (CML), which was potentially a marker of tissue chymase activity
Externí odkaz:
https://doaj.org/article/8bef7b3947f1478eaef0e8587c618f06